Peptides DB
Research-centric peptide and protocol reference hub
Study 44 of 47NAD+ (Nicotinamide Adenine Dinucleotide) literatureNature metabolism · ObservationalTop journal2026

Genetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilities.

Normalizing NADH levels alone is not enough to restore cell proliferation in primary human fibroblasts; both NADH and NADPH are crucial for metabolic health.

Read at Nature metabolismAdd to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
17
Preclinical
23
Observational · this one
1
Open-label
1
Randomised
5
Reviews

Summary and findings

This study investigates the effects of NADH-reductive stress and NADPH depletion in primary human fibroblasts and the role of a constitutively active Staphylococcus aureus NAD kinase (SaNADK) in restoring metabolic functions. The findings suggest that normalizing the NADH/NAD+ ratio alone is insufficient for cell proliferation recovery. The study also demonstrates that SaNADK can reverse proliferation arrest and senescence features in fibroblasts.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Nature metabolism supplied them

An elevated NADH/NAD<sup>+</sup> ratio (NADH-reductive stress) is a hallmark of mitochondrial dysfunction, yet how it drives pathologies ranging from primary mitochondrial disorders to ageing remains poorly understood<sup>1,2</sup>. Here, we show that mitochondrial respiratory chain inhibition in primary human fibroblasts induces NADH-reductive stress that coexists with profound NADPH depletion. Using the Escherichia coli soluble transhydrogenase (EcSTH)<sup>3</sup> to model this redox coupling in cells with intact mitochondria, we demonstrate that perturbation of both NAD(H) and NADP(H) redox pairs elicits metabolomic and transcriptomic reprogramming, culminating in proliferation arrest with senescence features. Notably, normalizing the NADH/NAD<sup>+</sup> ratio alone while NADPH depletion persists fails to rescue proliferation in EcSTH-expressing primary human cells, unlike in transformed HeLa cells. Stable isotope tracing reveals that primary fibroblasts rely more on NADPH-driven reductive carboxylation than HeLa cells, explaining why NADH/NAD<sup>+</sup> normalization alone is insufficient for rescue. To test this NADPH dependency, we develop a constitutively active Staphylococcus aureus NAD kinase (SaNADK) that expands the mammalian NADP(H) pool. In fibroblasts, SaNADK restores reductive carboxylation and de novo pyrimidine biosynthesis, and reverses proliferation arrest and senescence features. Furthermore, hepatic SaNADK expression in aged male mice partially alleviates transcriptional signatures of inflammation and metabolic dysregulation. Together, these findings establish EcSTH and SaNADK as xenotopic tools for dissecting NAD(P)H redox coupling and provide a framework for counteracting ageing-associated metabolic decline.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

CBioactive vitamin E-NAD<sup>+</sup> conjugate nanoparticles for osteoarthritis management via simultaneous suppression of inflammation and oxidative stress.Biomaterials · 2026 · Not reported in abstract.AnimalBNAD metabolism mediates a sex-specific protection against early life infectionsbiorxiv-preprint · 2026 · Higher birth NAD levels in females were associated with reduced infection burdens during the first 3 years of life.HumanBControl-referenced bacterial bioluminescence reveals a two-axis salivary response phenotype in benign and malignant breast disease.Talanta · 2026 · n=200 · Not reported in abstract.HumanDA context-dependent framework for targeting NAD metabolism in cancer.Cell metabolism · 2026reviewBPart 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injectionsbiorxiv-preprint · 2026 · 9.97% average daily increase in NAD+ for 100 mg IM.HumanBPart 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injectionsbiorxiv-preprint · 2026 · GlycoATP decreased at Day 30, p<0.05.Human